You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

CLINICAL TRIALS PROFILE FOR PURIXAN


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for PURIXAN

Trial ID Title Status Sponsor Phase Start Date Summary
NCT02228772 ↗ Phase I Study of MLN 9708 in Addition to Chemotherapy for the Treatment of Acute Lymphoblastic Leukemia in Older Adults Completed Millennium Pharmaceuticals, Inc. Phase 1 2014-12-01 This research study is evaluating a combination of drugs considered standard treatment for children and young adults with acute lymphoblastic leukemia (ALL), in combination with a new drug called MLN 9708. Additionally, the study is also evaluating if bone marrow or stem cell transplantation, which will be given to some participants, helps to prevent ALL from returning.
NCT02228772 ↗ Phase I Study of MLN 9708 in Addition to Chemotherapy for the Treatment of Acute Lymphoblastic Leukemia in Older Adults Completed Massachusetts General Hospital Phase 1 2014-12-01 This research study is evaluating a combination of drugs considered standard treatment for children and young adults with acute lymphoblastic leukemia (ALL), in combination with a new drug called MLN 9708. Additionally, the study is also evaluating if bone marrow or stem cell transplantation, which will be given to some participants, helps to prevent ALL from returning.
NCT03914625 ↗ A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia Recruiting National Cancer Institute (NCI) Phase 3 2019-06-28 This phase III trial studies how well blinatumomab works in combination with chemotherapy in treating patients with newly diagnosed, standard risk B-lymphoblastic leukemia or B-lymphoblastic lymphoma with or without Down syndrome. Monoclonal antibodies, such as blinatumomab, may induce changes in the body's immune system and may interfere with the ability of cancer cells to grow and spread. Drugs used in chemotherapy, such as vincristine, dexamethasone, prednisone, prednisolone, pegaspargase, methotrexate, cytarabine, mercaptopurine, doxorubicin, cyclophosphamide, and thioguanine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Leucovorin decreases the toxic effects of methotrexate. Giving monoclonal antibody therapy with chemotherapy may kill more cancer cells. Giving blinatumomab and combination chemotherapy may work better than combination chemotherapy alone in treating patients with B-ALL. This trial also assigns patients into different chemotherapy treatment regimens based on risk (the chance of cancer returning after treatment). Treating patients with chemotherapy based on risk may help doctors decide which patients can best benefit from which chemotherapy treatment regimens.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for PURIXAN

Condition Name

Condition Name for PURIXAN
Intervention Trials
Lymphoblastic Lymphoma 1
T-cell Adult Acute Lymphoblastic Leukemia 1
Acute Lymphoblastic Leukemia 1
B Acute Lymphoblastic Leukemia 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for PURIXAN
Intervention Trials
Precursor Cell Lymphoblastic Leukemia-Lymphoma 2
Lymphoma, Non-Hodgkin 2
Leukemia, Lymphoid 2
Leukemia 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for PURIXAN

Trials by Country

Trials by Country for PURIXAN
Location Trials
United States 48
Canada 8
Australia 5
New Zealand 2
Puerto Rico 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for PURIXAN
Location Trials
Massachusetts 2
Pennsylvania 1
Delaware 1
Texas 1
Connecticut 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for PURIXAN

Clinical Trial Phase

Clinical Trial Phase for PURIXAN
Clinical Trial Phase Trials
Phase 3 1
Phase 1 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for PURIXAN
Clinical Trial Phase Trials
Completed 1
Recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for PURIXAN

Sponsor Name

Sponsor Name for PURIXAN
Sponsor Trials
National Cancer Institute (NCI) 1
Millennium Pharmaceuticals, Inc. 1
Massachusetts General Hospital 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for PURIXAN
Sponsor Trials
Other 1
NIH 1
Industry 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.